Agony & Ecstasy Of Sarepta: A New FDA Rare Disease Standard?
Even though investors viewed the FDA's willingness to give Sarepta another chance to provide more data as a positive step, most analysts said it was simply delaying the inevitable of rejecting the firm's Duchenne muscular dystrophy drug eteplirsen. Others have cautioned the FDA may be setting a new standard for approving rare disease drugs, in which other companies may demand similar attention.
You may also be interested in...
The DMD community faces another setback as FDA pushes back timelines for Santhera and its respiratory drug, pushing the market to question what will come for other DMD treatments in development.
The biotech submitted an NDA to FDA for its DMD drug in hopes of succeeding where other companies have failed.
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.